AAV gene therapy vectors in the TMJ
Abstract Objectives The goal of this project was to evaluate the use of two adeno‐associated viral vector serotypes, adeno‐associated viral vectors (AAV)‐2 and AAV‐6, approved for and used for gene therapy in humans, for the delivery of therapeutic genes to the temporomandibular joint (TMJ) and the...
Saved in:
Main Authors: | Sabine M. Brouxhon (Author), Michael Kerry O'Banion (Author), Stephanos Kyrkanides (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Calcitonin gene‐related peptide: An intra‐articular therapeutic target for TMJ disorders
by: Sabine M. Brouxhon, et al.
Published: (2022) -
Reprogramming oral epithelial keratinocytes into a pluripotent phenotype for tissue regeneration
by: Fayrouz Bazina, et al.
Published: (2021) -
Conditional ablation of E‐cadherin in the oral epithelium progeny results in tooth anomalies
by: Stephanos Kyrkanides, et al.
Published: (2022) -
Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapy
by: Arun Srivastava
Published: (2023) -
Rapamycin immune tolerization enables gene transfer following subcutaneous delivery of AAV6 but not CD4-retargeted AAV6 vectors in AAV-seropositive rhesus macaques
by: K. Jerome, et al.
Published: (2019)